CIENCIASMEDICASNEWS: mayo 2026

domingo, 31 de mayo de 2026

Tracking Key Mental Health and Substance Use Policy Actions Under the Trump Administration Authors: Nirmita Panchal and Heather Saunders Published: May 26, 2026

https://www.kff.org/mental-health/tracking-key-mental-health-and-substance-use-policy-actions-under-the-trump-administration/ In 2024, over 61 million adults in the U.S. experienced a mental illness and deaths due to suicide, gun violence, and drug overdose remained high. Additionally, the COVID-19 pandemic and necessary public health responses exacerbated an already existing mental health and substance use crises. At the same time, many people experience difficulties affording mental health treatment or finding providers. Among insured adults who described their mental health as fair or poor, 43% reported at least one time in the past year when they needed mental health services or medication but did not receive them; some groups – including communities of color, youth and young adults – experience greater barriers.

Hantavirus Outbreak Revives COVID-Era False Health Claims Joel Luther , Hagere Yilma , and Irving Washington

https://www.kff.org/health-information-trust/hantavirus-outbreak-revives-covid-era-false-health-claims/ A hantavirus outbreak linked to a Dutch cruise ship in early May was followed by false health claims that mirror patterns documented in previous outbreaks. The Monitor also examines a new analysis of Americans’ relationship with health and wellness influencers.

New Ebola Quarantine Rule Bars Entry of Noncitizens, Including Green Card Holders, from Affected Countries Published: May 29, 2026

https://www.kff.org/quick-insights/new-ebola-quarantine-rule-bars-entry-of-noncitizens-including-green-card-holders-from-affected-countries/ The rule is significantly more restrictive than approaches used to mitigate risks during past Ebola outbreaks and creates a standing administrative authority that may allow the CDC to quickly issue suspensions or place strict restrictions on entry of any noncitizen, including lawful permanent residents, under situations it deems to be high-risk public health emergencies in the future.

Kidney cancer study finds belzutifan + pembrolizumab post-surgery helps patients stay cancer-free longer

https://www.statnews.com/sponsor/2026/05/29/kidney-cancer-study-finds-belzutifan-pembrolizumab-post-surgery-helps-patients-stay-cancer-free-longer/

Revolution Medicines starts shipping experimental pancreatic cancer drug Life-extending data for daraxonrasib create high patient demand even without FDA approval

https://www.statnews.com/2026/05/30/pancreatic-cancer-daraxonrasib-revolution-medicines-early-access-asco-2026/ By Adam FeuersteinMay 30, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.

For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds Protocol could become a third option for high risk, early stage cases

https://www.statnews.com/2026/05/31/prostate-cancer-hormone-therapy-cut-relapse-asco-2026/ By Angus ChenMay 31, 2026 Cancer Reporter

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer ‘Two drugs in one’ candidate, developed in China, is a highlight at ASCO

https://www.statnews.com/2026/05/31/squamous-cell-lung-cancer-akeso-summit-harmoni-asco-2026/ By Matthew HerperMay 31, 2026 Senior Writer, Medicine, Editorial Director of Events

Practice-changing results reported for Revolution Medicines pancreatic cancer drug Daraxonrasib nearly doubled survival time compared to standard chemotherapy

https://www.statnews.com/2026/05/31/pancreatic-cancer-daraxonrasib-revolution-medicines-results-asco-2026/ By Adam FeuersteinMay 31, 2026 Senior Writer, Biotech

Medscape Medical News Conference News ASCO 2026 Selpercatinib Cuts Recurrence Risk in Early RET+ Non-Small Cell Lung Cancer Will Pass May 31, 2026

https://www.medscape.com/viewarticle/selpercatinib-cuts-recurrence-risk-early-ret-non-small-cell-2026a1000i25 Adjuvant selpercatinib improves event-free survival (EFS) in patients with early-stage, RET fusion-positive non-small cell lung cancer (NSCLC) who have undergone definitive surgery or radiation, based on results of the first phase 3 trial to use a RET inhibitor as adjuvant therapy. https://www.medscape.com/c25/p14/american-society-clinical-oncology-asco-2026-2026a1000c7g

IMPACT EBC: IMPlementing Advances in Cancer Treatment for Patients With HR+/HER2- Early Breast Cancer - Moving Patient Care Forward

IMPACT EBC: IMPlementing Advances in Cancer Treatment for Patients With HR+/HER2- Early Breast Cancer - Moving Patient Care Forward Approximately 30% of patients with early breast cancer (EBC) will eventually develop metastatic disease. In hormone receptor (HR)-positive breast cancer, approximately 50% of recurrences occurs within 5 years of diagnosis. Many factors should be considered when evaluating a patient's risk of recurrence, including HR status, and human epidermal growth factor receptor 2 (HER2) status, nodal involvement, histologic grade, anatomic stage, positive or close margins, proliferate rate, tumor size, and the patient's age and health status. IMPlementing Advances in Cancer Treatment for Patients With HR-Positive, HER2-Negative Early Breast Cancer is a collection of educational programs designed for clinicians to stay up to date on the clinical data that supports decision-making for patients with HR-positive, HER2-negative EBC at risk of recurrence and make an IMPACT on patient outcomes and quality of life. https://www.medscape.org/advances/implementing-advances-cancer-treatment-patients-hr-her2-2025a1000yzz

Integrating SCLC Guideline Updates on Lambert-Eaton Myasthenic Syndrome into Practice: Expert Case Conversations Authors: David E. Gerber, MD; Tuan H. Vu, MD; Jacob M. Sands, MD

https://www.medscape.org/viewarticle/integrating-sclc-guideline-updates-lambert-eaton-myasthenic-2026a1000gtp?page=1

Ready for Launch in Gastroesophageal Adenocarcinoma: Anti-HER2 Innovation in First-Line Management Authors: Elena Elimova, MD; Zev Wainberg, MD; Filippo Pietrantonio, MD

https://www.medscape.org/viewarticle/ready-launch-gastroesophageal-adenocarcinoma-anti-her2-2026a1000gtw?page=1

The Molecular Nuances of Hemostasis: Differentiating FVIII and Non-Factor Replacement Authors: Maria Elisa Mancuso, MD, PhD; Yesim Dargaud, MD, PhD

https://www.medscape.org/viewarticle/molecular-nuances-hemostasis-differentiating-fviii-and-non-2026a1000hk2?page=1

Precision Oncology Meets RAS: Innovations in Targeting RAS-Addicted Solid Tumors Authors: Kathryn C. Arbour, MD; Aparna R. Parikh, MD, MS

https://www.medscape.org/viewarticle/precision-oncology-meets-ras-innovations-targeting-ras-2025a1000x8k?page=1&src=mkmcmr_driv_stan_mscpedu_260531-OUS-HONC-precision-oncology-meets-ras-innovations-targeting-ras-2025a1000x8k-cta&uac=148436CN

Editorial p365 Putting placebo effects in a new light The Lancet Psychiatry +... + + +...

Editorial p365 Putting placebo effects in a new light The Lancet Psychiatry https://www.thelancet.com/journals/lanpsy/issue/vol13no5/PIIS2215-0366(26)X2003-X Confirmatory efficacy and safety trial of magnetic seizure therapy versus right unilateral ultra-brief electroconvulsive therapy in depression (CREST–MST): a randomised, double-blind, non-inferiority trial in Canada and the USA Prof Daniel M Blumberger, MDa,b Send email to daniel.blumberger@camh.ca ∙ Prof Shawn M McClintock, PhDe,f ∙ Kevin E Thorpe, MMathc,g ∙ Prof Carol A Tamminga, MDe ∙ Karen Foleyd,h ∙ Prof Mustafa M Husain, MDe ∙ et al. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(26)00060-X/fulltext?dgcid=hubspot_email_infocusalerts-psychiatry_feature&utm_campaign=infocusalerts-psychiatry&utm_medium=email&_hsenc=p2ANqtz-_rIMPVmPSlOLAsVVcU_fgdNunUrJJtq6bKqVfIK3Hp2taBPEDB92YuVjoTu_WWwF4ppAdFmLLTagrvklWHUNbWO4t5Kg&_hsmi=421429175&utm_content=420563001&utm_source=hs_email The effectiveness of psychosocial interventions for self-harm in males compared to females: a systematic review and meta-analysis Oliver Matias Send email to Oliver.Matias@citystgeorges.ac.uk ∙ Alexandra E. Bakou ∙ Kirsten Barnicot ∙ Rose McCabe https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(26)00018-9/fulltext?dgcid=hubspot_email_infocusalerts-psychiatry_feature&utm_campaign=infocusalerts-psychiatry&utm_medium=email&_hsenc=p2ANqtz--Z8g6L-OgGMy0jkBb4veLLRUa1Hg9ICUoqTW-j4lcXox1np6FUrup3WHs-vrfkBieZlC7MHVUDG7hkdmDPd69zNDFxBg&_hsmi=421429175&utm_content=420563001&utm_source=hs_email Editorial Humanity first, not country first The Lancet Regional Health – Europe https://www.thelancet.com/journals/lanepe/issue/vol63nonull/PIIS2666-7762(25)X0014-4

Gene clock predicts time to death in humans — and assesses ‘biological’ age Cellular-ageing clocks based on gene activity could be more sensitive than previous measures. By Heidi Ledford

https://www.nature.com/articles/d41586-026-01661-y?utm_source=Live+Audience&utm_campaign=2f2a6b7480-nature-briefing-daily-20260527_COPY_01&utm_medium=email&utm_term=0_-33f35e09ea-50432164 A powerful molecular clock calibrated using data on gene activity from thousands of individuals can predict biological ageing in rodents, monkeys and humans — and time to death in people1.

FDA approves durvalumab in combination with Bacillus Calmette-Guerin for high-risk non-muscle invasive bladder cancer

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-combination-bacillus-calmette-guerin-high-risk-non-muscle-invasive-bladder On May 28, 2026, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) in combination with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC).

Mastering Oral Therapies in CLL and MCL: Essential Strategies and Insights for Nurses Authors: Amy L. Goodrich, RN, MSN, CRNP-AC; Claudia Boglione, RN; Natacha Bolanos

https://www.medscape.org/viewarticle/mastering-oral-therapies-cll-and-mcl-essential-strategies-2025a1000xko?page=1&src=mkmcmr_driv_stan_mscpedu_260530-OUS-HONC-mastering-oral-therapies-cll-and-mcl-essential-strategies-2025a1000xko-cta&uac=148436CN

Advancing Personalized Care for Prostate Cancer: Patient-Centered Solutions for mHSPC and nmCRPC Authors: Alicia K. Morgans, MD, MPH, FASCO; Christian Gratzke, MD; Fred Saad, MD, FRCS, FCAHS; Tony Collier, BEM

https://www.medscape.org/viewarticle/advancing-personalized-care-prostate-cancer-patient-centered-2025a1000uyb?page=1&src=mkmcmr_driv_stan_mscpedu_260530-OUS-HONC-advancing-personalized-care-prostate-cancer-patient-centered-2025a1000uyb-cta&uac=148436CN

Therapeutic Evolution in mHSPC: Analyzing Emerging Combinations and Outcomes Authors: Rana R. McKay, MD, FASCO; Alicia K. Morgans, MD, MPH, FASCO; David Morris, MD, FACS

https://www.medscape.org/viewarticle/therapeutic-evolution-mhspc-analyzing-emerging-combinations-2026a100087o?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_260530-OUS-HONC-therapeutic-evolution-mhspc-analyzing-emerging-combinations-2026a100087o-cta

sábado, 30 de mayo de 2026

New approach helps design better antibiotics to fight drug-resistant infections

https://www.news-medical.net/news/20260529/New-approach-helps-design-better-antibiotics-to-fight-drug-resistant-infections.aspx A new way of designing antibiotics could support the discovery of new treatments for drug-resistant infections. It could also help revive antibiotics that have lost effectiveness because bacteria have evolved over time to survive the drugs meant to kill them.

Novel therapeutic agent proposed to combat drug resistant tuberculosis

https://www.news-medical.net/news/20260529/Novel-therapeutic-agent-proposed-to-combat-drug-resistant-tuberculosis.aspx A research team led by Associate Professor Noriyuki Kurita from the Department of Computer Science and Engineering at Toyohashi University of Technology and by Associate Professor Pornpan Pungpo from Ubon Ratchathani University in Thailand has proposed a novel therapeutic agent for tuberculosis, using high-precision molecular simulation techniques. The proposed drug is anticipated to bind strongly to the drug-metabolizing enzyme cytochrome P450 (CYP), thereby inhibiting excessive CYP-mediated metabolism and preventing the degradation of co-administered drugs. Additionally, because this agent targets enzymes released by the tuberculosis bacterium rather than the bacterium itself, the likelihood of bacterial mutation and resistance development is reduced, suggesting sustained therapeutic efficacy over an extended period.

Targeted therapy sunvozertinib outperforms standard chemotherapy in advanced lung cancer trial

https://www.news-medical.net/news/20260529/Targeted-therapy-sunvozertinib-outperforms-standard-chemotherapy-in-advanced-lung-cancer-trial.aspx The targeted therapy sunvozertinib was more effective than standard platinum-based chemotherapy as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) driven by EGFR exon 20 insertion mutations (EGFR exon20ins), according to new research from The University of Texas MD Anderson Cancer Center.

Consumer wearables become the new gatekeepers of clinical health care

https://www.news-medical.net/news/20260529/Consumer-wearables-become-the-new-gatekeepers-of-clinical-health-care.aspx JMIR Publications today released a News and Perspectives expert analysis on consumer wearable platforms' forays into the clinical health care space. Authored by MedTech expert Blythe Karow, MBA, "Meet the New Health Care Gatekeeper: Your Wearable" lays out the implications of wearable tech companies owning the first conversation about a patient's health, as well as the potential impacts on patient trust, policy, and regulation.

Teclistamab delivers deeper responses in relapsed myeloma patients

https://www.news-medical.net/news/20260529/Teclistamab-delivers-deeper-responses-in-relapsed-myeloma-patients.aspx Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in remission far longer than those receiving standard therapies, according to results from a major international phase 3 clinical trial published in The New England Journal of Medicine and presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

Thyroid function linked to chronotype or daytime sleepiness in women with Hashimoto's thyroiditis

https://www.news-medical.net/news/20260529/Thyroid-function-linked-to-chronotype-or-daytime-sleepiness-in-women-with-Hashimotos-thyroiditis.aspx Hashimoto's thyroiditis (HT), an autoimmune disease with a prevalence 2–7 times higher in women than in men, is associated with daytime sleepiness. The present study aimed to test the hypothesis that thyroid function is associated with chronotype and daytime sleepiness in women with HT.

Gene test helps many breast cancer patients avoid chemotherapy

https://www.news-medical.net/news/20260529/Gene-test-helps-many-breast-cancer-patients-avoid-chemotherapy.aspx Many people with breast cancer can safely avoid chemotherapy with the use of a gene test, potentially sparing them unnecessary side effects without increasing the risk of the cancer returning, a large international clinical trial led by UCL has found. The OPTIMA trial (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) was designed to reduce the use of unnecessary chemotherapy for people with newly diagnosed breast cancer. It followed more than 4,400 patients across the UK, Norway, Sweden, Australia, New Zealand and Thailand.

Pembrolizumab combination therapy improves survival in recurrent endometrial cancer patients

https://www.news-medical.net/news/20260529/Pembrolizumab-combination-therapy-improves-survival-in-recurrent-endometrial-cancer-patients.aspx Previously, immature overall survival results of the NRG Oncology GY018 (NRG-GY018) trial suggested that the use of the immunotherapy drug pembrolizumab in combination with chemotherapy improved overall survival for patients with advanced stage or recurrent endometrial cancer when compared to chemotherapy alone. Notably, this benefit was observed in both the mismatch repair proficient (pMMR) and mismatch repair deficient (dMMR) populations. An analysis of the study data, with prolonged follow-up, demonstrated that there was a sustained numerical benefit in overall survival for patients who received pembrolizumab with chemotherapy even when a large proportion of the initial placebo treated patients received post-protocol immunotherapy. These results were presented during the Gynecologic Oncology Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

Researchers uncover new clues about the origin of Alzheimer's tau tangles

https://www.news-medical.net/news/20260529/Researchers-uncover-new-clues-about-the-origin-of-Alzheimers-tau-tangles.aspx Researchers at Columbia University have uncovered new clues about the earliest molecular events that may trigger Alzheimer's disease, shedding light on how toxic tau filaments begin to form in the brain. The findings could help guide future therapies aimed at stopping the disease before significant memory loss and cognitive decline occur.

Fruit fly study links dopamine to stress-induced sexual dysfunction

https://www.news-medical.net/news/20260530/Fruit-fly-study-links-dopamine-to-stress-induced-sexual-dysfunction.aspx Scientists from Tokyo Metropolitan University have revealed key parts of the biochemical pathways connecting stress to sexual dysfunction. By studying Drosophila fruit flies, they showed that the neurotransmitter dopamine was responsible for determining how long male flies showed persistent courtship suppression after being confined in a small space, but not whether mating was suppressed in the first place. Their findings in a key model organism illuminate neurobiological factors causing sexual dysfunction in other organisms, including humans.

Could guava juice help prevent anemia?

https://www.news-medical.net/news/20260529/Could-guava-juice-help-prevent-anemia.aspx An inexpensive tropical fruit may help tackle one of the world's most common nutritional deficiencies, with researchers finding that guava juice can significantly improve hemoglobin levels in women and girls. A systematic review from Indonesia, published in the journal BMJ Nutrition, Prevention & Health, indicates that adding guava juice to the diet could boost hemoglobin levels in adolescent girls and pregnant women. This could potentially offer a low-cost dietary complement to iron supplementation, given the high prevalence of iron-deficiency anemia among females, especially in low- and middle-income countries (LMICs).

Making older women more visible in healthy ageing The Lancet Regional Health – Western Pacific ++... ++

Making older women more visible in healthy ageing The Lancet Regional Health – Western Pacific https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(26)00095-7/fulltext May 2026 Volume 70 https://www.thelancet.com/journals/lanwpc/issue/vol70nonull/PIIS2666-6065(26)X2003-X Adaptive functioning in school-aged children with spinal muscular atrophy in the treatment era: a non-randomised cohort study Emily E. Faraha ∙ Sarah-Grace Paguintoa,c ∙ Melissa R. Mandarakasa,b ∙ Karen Herberta,b ∙ Smriti Krishand ∙ Hugo Sampaiob ∙ et al. https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(26)00070-2/fulltext?dgcid=raven_jbs_etoc_feature_lanwpc Critical care access and outcomes in residents of inpatient-care catchment areas with and without ICUs: a nationwide cohort study in Japan Hiroyuki Ohbea,b Send email to hohbey@gmail.com ∙ Nobuaki Shimec ∙ Kei Nishiyamad ∙ Takuya Satoe ∙ Kent Doie ∙ Kiyohide Fushimif ∙ et al. https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(26)00072-6/fulltext?dgcid=raven_jbs_etoc_feature_lanwpc

Efficacy and Safety of Bodyweight-Adjusted Higher Dose of Ocrelizumab in Relapsing (MUSETTE) and Primary Progressive (GAVOTTE) Multiple Sclerosis

https://www.thelancet.com/infographics-do/musette-gavotte-graphical-abstract-26?dgcid=hubspot_email_infocusalerts-neurology_feature_lancetneuro26&utm_campaign=infocusalerts-neurology&utm_medium=email&_hsenc=p2ANqtz--sD6cEE8wbxtYciMUDkVOnSbZft_x4ThKFFX7dETUNQ9txz1oQ6c2G6ozjT8dddmTpXI-yaqyqbthsWIMlU8wIBCFLHQ&_hsmi=421331774&utm_content=420563000&utm_source=hs_email

Editorial p2141 A new era in neurology The Lancet + +... + +

Comparison of [18F]flortaucipir and [18F]MK6240 for the detection of tau pathology in Alzheimer's disease (HEAD): a multicentre, prospective, cross-sectional, within-participant study Guilherme Povala, PhDa,* ∙ Bruna Bellaver, PhDa,* ∙ Firoza Z Lussier, MSa ∙ Livia Amaral, MSa ∙ Guilherme Bauer-Negrini, PhDa ∙ Pamela C L Ferreira, PhDa ∙ et al. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00417-4/fulltext?dgcid=hubspot_email_infocusalerts-neurology_feature_lancetneuro26&utm_campaign=infocusalerts-neurology&utm_medium=email&_hsenc=p2ANqtz-8ujTQJDAYhslHYBGpDUpx_0K9Os9kmp4PeAcWF_2cuB18ftCv178Pqz1vfY_YQeOAe2ZXPwgzy1Rc4OhQ7sVseVHNJ4g&_hsmi=421331774&utm_content=420563000&utm_source=hs_email Editorial p2141 A new era in neurology The Lancet https://www.thelancet.com/journals/lancet/issue/vol407no10544/PIIS0140-6736(26)X2019-0 Alzheimer's disease Alberto Serrano-Pozo, MD PhDa,b,c Send email to aserrano1@mgh.harvard.edu ∙ Prof Valentina Escott-Price, PhDd,e ∙ Prof Lea T Grinberg, MD PhDf ∙ Tharick Pascoal, MD PhDg,h ∙ Marc Suárez-Calvet, MD PhDi,j ∙ Prof Bruno Dubois, MDk,l ∙ et al. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00198-4/abstract?utm_campaign=infocusalerts-neurology&utm_medium=email&dgcid=hubspot_email_infocusalerts-neurology_feature_lancetneuro26&_hsenc=p2ANqtz-9k3jQnYevg0uj5SxI80gLmEfvlwjqHWAJYtswfqGMfseP5cQL0HW6IdEf9fVGrTyGlMLAlvimkY2sVkLdOyypZB_YllA&_hsmi=421331774&utm_content=420563000&utm_source=hs_email Integrating peripheral immune control and brain health in the multiple sclerosis continuum Eleonora Cocco https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00829-9/abstract?utm_campaign=infocusalerts-neurology&utm_medium=email&dgcid=hubspot_email_infocusalerts-neurology_feature_lancetneuro26&_hsenc=p2ANqtz-8GWqCa3ivRgyNXD2SXoIwEPV0MBEjA9PEJArb61cwurvs-NTfuKQ-qNhY8dWMK4FM6GUMrdaRKd4NkFa8zVm2ojHoviQ&_hsmi=421331774&utm_content=420563000&utm_source=hs_email

Tile-Based Radiation to Treat Large Brain Metastases? M. Alexander Otto, PA, MMSc May 30, 2026

https://www.medscape.com/viewarticle/tile-based-radiation-treat-large-brain-metastases-2026a1000i1s A radiation therapy implant demonstrated significantly improved surgical bed control and longer overall survival compared to standard stereotactic radiotherapy (SRT) after resection of large brain metastases, according to a phase 3 trial. https://www.medscape.com/c25/p14/american-society-clinical-oncology-asco-2026-2026a1000c7g

Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL M. Alexander Otto, PA, MMSc May 30, 2026

https://www.medscape.com/viewarticle/tafasitamab-combo-boosts-r-chop-frontline-dlbcl-2026a1000i14 Adding tafasitamab and lenalidomide to rituximab, cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone (R-CHOP) improves outcomes in newly diagnosed diffuse large B-cell lymphoma and high-grade B-cell lymphoma, according to the phase 3 frontMIND trial. https://www.medscape.com/c25/p14/american-society-clinical-oncology-asco-2026-2026a1000c7g

More Patients With Breast Cancer Can Skip Axillary Dissection Will Pass May 30, 2026

https://www.medscape.com/viewarticle/more-patients-breast-cancer-can-skip-axillary-dissection-2026a1000i1u Women with breast cancer and 1-2 sentinel lymph node macrometastases can safely skip completion axillary lymph node dissection (ALND) without compromising overall survival or arm function, according to new data from the largest randomized trial of its kind to date.

Highlights From the Annual Neuro-Oncology Conference: Redefining IDH-Mutant Glioma Management Authors: Evanthia Galanis, MD; Shawn Hervey-Jumper, MD; Katherine B. Peters, MD, PhD, FAAN; Matthias Preusser, MD

https://www.medscape.org/viewarticle/1003198?src=mkmcmr_driv_stan_mscpedu_260529-OUS-HONC-1003198-cta&uac=148436CN

Treating Metastatic Colorectal Cancer in the Second Line and Beyond: Oral Therapy Edition Authors: Rahul Gosain, MD, MBA; Rohit Gosain, MD; John Strickler, MD; Chiara Cremolini, MD, PhD

https://www.medscape.org/viewarticle/1003002?uac=148436CN&src=mkmcmr_driv_stan_mscpedu_260529-OUS-HONC-1003002-cta

Safer Stroke Prevention on the Horizon? What the New Factor XIa Inhibitor Data Reveal Authors: Eva A. Mistry, MBBS, MSCI, FAHA; Yi Dong, MD; Xin Cheng, MD, PhD; Mike Sharma, MD, MSc, FRCPC; Ashkan Shoamanesh, MD, PhD

https://www.medscape.org/viewarticle/safer-stroke-prevention-horizon-what-new-factor-xia-2026a10004zj?page=1&src=mkmcmr_driv_stan_mscpedu_260530-OUS-HONC-safer-stroke-prevention-horizon-what-new-factor-xia-2026a10004zj-cta&uac=148436CN

The Potential for Remission, Cure in Psoriasis With Biologic Treatment: A Q&A With Andrew Blauvelt, MD, MBA Christine Kilgore May 27, 2026 ++++ ++++

The Potential for Remission, Cure in Psoriasis With Biologic Treatment: A Q&A With Andrew Blauvelt, MD, MBA Christine Kilgore https://www.medscape.com/viewarticle/potential-remission-cure-psoriasis-biologic-treatment-q-2026a1000hlg?ecd=mkm_ret_260530_mscpmrk_derm_biologics-in-derm_etid8382686&uac=148436CN&impID=8382686 May 27, 2026 Andrew Blauvelt, MD, MBA, began to study psoriasis in depth in Portland, Oregon, over 20 years ago, after spending several years at the National Institutes of Health training in cellular immunology and working as a senior investigator on HIV. In Portland, he was a professor at Oregon Health & Science University, where he conducted basic science research on the immunology of psoriasis, with a focus on how interleukin (IL)-23 and Th17 cells contribute to psoriasis pathogenesis. Biologics Continue to Transform Psoriasis Care, Giving Physicians and Patients More Options Damian McNamara, MA https://www.medscape.com/viewarticle/biologics-continue-transform-psoriasis-care-giving-2026a1000hs6?ecd=mkm_ret_260530_mscpmrk_derm_biologics-in-derm_etid8382686&uac=148436CN&impID=8382686 May 28, 2026 This is the second installment of a four-part series on biologics and dermatology, further exploring the impact of biologics in the treatment of dermatologic diseases. Future installments will focus on atopic dermatitis and other skin diseases. Exciting Developments in Psoriasis From AAD 2026 Shawn G. Kwatra, MD https://www.medscape.com/viewarticle/updates-psoriasis-and-related-disorders-aad-2026-2026a10008be?ecd=mkm_ret_260530_mscpmrk_derm_biologics-in-derm_etid8382686&uac=148436CN&impID=8382686 Clinical Impact of AAD 2026: Integrating Weight Management into Psoriasis Care Tina Bhutani, MD, MAS https://www.medscape.com/viewarticle/mdangle-aad-2026-psoriasis-clinical-impact-2026a10005ba?ecd=mkm_ret_260530_mscpmrk_derm_biologics-in-derm_etid8382686&uac=148436CN&impID=8382686 Expert Guidance on Switching, Stacking Systemic Therapies for Psoriasis Damian McNamara, MA https://www.medscape.com/viewarticle/expert-guidance-switching-stacking-systemic-therapies-2026a1000gyp?ecd=mkm_ret_260530_mscpmrk_derm_biologics-in-derm_etid8382686&uac=148436CN&impID=8382686 May 25, 2026 How Much Monitoring Is Enough in Psoriasis Care? Steven R. Feldman, MD, PhD; Jennifer C. Cather, MD; Brad P. Glick, DO, MPH, FAAD, FAOCD https://www.medscape.com/ca8/p04/podcast-psoriasis-s4-ep3-2026a10006hk?ecd=mkm_ret_260530_mscpmrk_derm_biologics-in-derm_etid8382686&uac=148436CN&impID=8382686 Identifying Lesions on Skin of Color Carly A. Elston, MD; Dirk M. Elston, MD https://reference.medscape.com/p11/identifying-lesions-skin-color-2026a1000eg1?ecd=mkm_ret_260530_mscpmrk_derm_biologics-in-derm_etid8382686&uac=148436CN&impID=8382686 National Psoriasis Foundation Outlines Role of GLP-1 RAs for Psoriasis Ted Bosworth https://www.medscape.com/viewarticle/national-psoriasis-foundation-outlines-role-glp-1-ras-2026a1000ear?ecd=mkm_ret_260530_mscpmrk_derm_biologics-in-derm_etid8382686&uac=148436CN&impID=8382686

viernes, 29 de mayo de 2026

Most Read Cancer Science & Oncogenesis +...

https://read.qxmd.com/collection/1133?ecd=wnl_readmost_260529 Triple-negative breast cancer: current understanding and future perspectives. Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype defined by the absence of estrogen receptors, progesterone receptors, and human epid.. 2026: Exploration of targeted anti-tumor therapy.

Interprofessional Approach to Adverse Event Care for the Patient With High-Risk Hormone Receptor-Positive/HER2-Negative Early Breast Cancer Authors: Jonathan Malara, PharmD, BCOP; Nelli Zafman, CRNP, MSN, AOCNP

https://www.medscape.org/viewarticle/interprofessional-approach-adverse-event-care-patient-high-2026a1000gez?page=1

Fact vs. Fallacy: Challenging the Norms of Cancer Care Fallacies in Medicine Bishal Gyawali, MD, PhD

https://www.medscape.com/viewarticle/fact-vs-fallacy-challenging-norms-cancer-care-fallacies-2026a1000gei Hello, everyone. This is Dr Bishal Gyawali, from Queens University, Kingston, Canada. Today, I’m back with you to talk about some of the fallacies that I have seen in medicine, oncology, and the drug regulatory space. I wanted to clarify some of these fallacies.

American Society of Clinical Oncology (ASCO) 2026

https://www.medscape.com/c25/p14/american-society-clinical-oncology-asco-2026-2026a1000c7g

Which Patients With Early HCC Should Undergo Resection? Daniela Barros l Medscape Europe May 29, 2026

https://www.medscape.com/viewarticle/which-patients-early-hcc-should-undergo-resection-2026a1000hwk For years, patients with early-stage hepatocellular carcinoma (HCC) who had multiple liver nodules were typically referred for less-invasive locoregional therapies such as radiofrequency ablation (RFA) and transarterial chemoembolization (TACE). The logic seemed sound: to avoid surgical trauma in people who often already have cirrhosis or limited liver function. Now, a new national multicenter meta-analysis suggests that, in carefully selected patients, this approach may need to be reconsidered.

CAR-T Therapy Shows Promise in CNS and Extramedullary B-ALL Edited by Gargi Mukherjee May 29, 2026

https://www.medscape.com/viewarticle/car-t-therapy-shows-promise-cns-and-extramedullary-b-all-2026a1000hyx CD19 chimeric antigen receptor (CAR) T-cell therapy achieved high response rates in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and extramedullary disease or central nervous system (CNS) involvement, according to a retrospective review. More than 80% of patients achieved clearance of their extramedullary or CNS disease; however, patients with concurrent high bone marrow disease burden experienced significantly worse survival than those with low bone marrow burden.

A single viral platform shows promise across infectious disease and cancer ReiThera’s gorilla-derived adenovirus vector is helping advance vaccines and therapies for COVID-19, HIV, Ebola, and even cancer. Written byBree Foster, PhD

A single viral platform shows promise across infectious disease and cancer ReiThera’s gorilla-derived adenovirus vector is helping advance vaccines and therapies for COVID-19, HIV, Ebola, and even cancer. Written byBree Foster, PhD https://www.drugdiscoverynews.com/a-single-viral-platform-shows-promise-across-infectious-disease-and-cancer-17103?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_Tdx3m2iMvdp1D3k42S5hPo1PrPtt3IjBfdsUwgZ-0LEAiv-XA5590T3h9k7W1V0wPFzJZ4rS9-snPUOaMSLUTIou5bg&_hsmi=421171733&utm_content=421171733&utm_source=hs_email At Advanced Therapies 2026, DDN spoke with Claudio Panzarella, Head of Business Development, and Angelo Raggioli, Head of Technology Development, at ReiThera, about how the company’s early COVID-19 vaccine efforts shaped its current scientific programs, including the gorilla adenovirus (GRAd) platform, ongoing HIV vaccine trials, and the potential for oncology therapeutics.

Ultrasound-triggered nanocatchers turn tumors into personalized vaccines The approach pairs ultrasound-induced tumor cell death with real-time antigen capture to drive both local and systemic immune responses. Written byAndrea Corona

Ultrasound-triggered nanocatchers turn tumors into personalized vaccines The approach pairs ultrasound-induced tumor cell death with real-time antigen capture to drive both local and systemic immune responses. Written byAndrea Corona https://www.drugdiscoverynews.com/ultrasound-triggered-nanocatchers-turn-tumors-into-personalized-vaccines-16921?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8cYDfDkA7hLpNiUtfdXSdBDOWTg0LnoRAnLedX9FV9zUCHeyTuubBA8-NHcn3eg-gjRUFSkVliklr1_12zV6qe7O48bQ&_hsmi=421171733&utm_content=421171733&utm_source=hs_email A research team in China has developed an ultrasound-responsive nanomaterial that can capture tumor antigens within the tumor microenvironment, addressing one of the central challenges in cancer immunotherapy: how to generate patient-specific immune responses in the face of extreme tumor heterogeneity.

Can one drug repair the brain across multiple CNS diseases? A first-in-class synaptic regenerative approach shows promise across multiple neurodegenerative and neuropsychiatric diseases. Written byBree Foster, PhD

Can one drug repair the brain across multiple CNS diseases? A first-in-class synaptic regenerative approach shows promise across multiple neurodegenerative and neuropsychiatric diseases. Written byBree Foster, PhD https://www.drugdiscoverynews.com/can-one-drug-repair-the-brain-across-multiple-cns-diseases-17191 The human brain contains roughly one hundred billion neurons arranged in extremely intricate networks that generate every thought, memory, emotion, and dream, and coordinate our ability to perceive, respond to, and interact with the world. These remarkable capabilities are only possible if neurons can efficiently coordinate with other cells in the network, using specialized junctions known as synapses.

Weekly Rundown: Oxford scientists develop rapid Ebola vaccine as Congo outbreak grows FDA approvals, pharma deals, and genetic testing advancements led the news this week. Written byDDN editorial team

Weekly Rundown: Oxford scientists develop rapid Ebola vaccine as Congo outbreak grows FDA approvals, pharma deals, and genetic testing advancements led the news this week. Written byDDN editorial team https://www.drugdiscoverynews.com/weekly-rundown-oxford-scientists-develop-rapid-ebola-vaccine-as-congo-outbreak-grows-17195?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9CaSYgo64yBacJHTMjO0uKmroqOegAhmVtlluB9iWyyDXKDHmEvlq9T9XJICNraOUq19CuKzvGGM2JLTybPa_2yKsXAg&_hsmi=421171733&utm_content=421171733&utm_source=hs_email Scientists at the University of Oxford are developing an experimental Ebola vaccine that could be ready for clinical trials within two to three months, as health authorities race to contain an outbreak in the Democratic Republic of Congo that has caused around 750 suspected cases and 177 deaths. The outbreak, driven by the rare Bundibugyo strain of Ebola has been classified by the World Health Organization as a “very high” risk nationally, with a declared public health emergency of international concern. The Oxford team’s candidate uses the ChAdOx1 viral vector platform, previously deployed in the COVID-19 vaccine developed with AstraZeneca, to deliver genetic material from the Bundibugyo virus via a modified chimpanzee cold virus that cannot cause disease but trains the immune system to recognize the pathogen. While animal studies are now under way and production plans are being prepared with the Serum Institute of India, researchers stress that the vaccine’s effectiveness remains unproven and depends on preclinical and early clinical results. – Bree Foster

Hot Topics from Berlin 2025: What Experts Say About the Future of Metastatic Breast Cancer Care Authors: Paolo Tarantino, MD, PhD; Valentina Guarneri, MD, PhD; Rebecca A. Dent, MD

https://www.medscape.org/viewarticle/hot-topics-berlin-2025-what-experts-say-about-future-2025a1000x8r?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_260528-OUS-HONC-hot-topics-berlin-2025-what-experts-say-about-future-2025a1000x8r-cta

The Next Frontier in Metastatic CRPC: The EZH2 Pathway and Emerging Therapies Authors: Elena Castro, MD, PhD; Michael Schweizer, MD; Neal D. Shore, MD, FACS

https://www.medscape.org/viewarticle/next-frontier-metastatic-crpc-ezh2-pathway-and-emerging-2026a10009uq?page=1&src=mkmcmr_driv_stan_mscpedu_260528-OUS-HONC-next-frontier-metastatic-crpc-ezh2-pathway-and-emerging-2026a10009uq-cta&uac=148436CN

Optimizing the Transplant Experience: A Patient Journey Through Conditioning and GvHD Management Authors: Daniele Avenoso, MD, PhD; Filippo Milano, MD, PhD; Mareike Verbeek, MD; Robert Zeiser, MD

https://www.medscape.org/viewarticle/optimizing-transplant-experience-patient-journey-through-2026a1000bh8?page=1&src=mkmcmr_driv_stan_mscpedu_260529-OUS-HONC-optimizing-transplant-experience-patient-journey-through-2026a1000bh8-cta&uac=148436CN

New Clinical Trial Testing On-Demand Use of Deucrictibant in Patients With Hereditary Angioedema by Madaline Spencer| Published on: Mar 20, 2026

New Clinical Trial Testing On-Demand Use of Deucrictibant in Patients With Hereditary Angioedema by Madaline Spencer| Published on: Mar 20, 2026 Peng Lu, MD, PhD, Chief Medical Officer at Pharvaris, and Wim Souverijns, PhD, Chief Commercial Officer at Pharvaris, discuss the RAPIDe-3 clinical trial of deucrictibant for patients with hereditary angioedema (HAE). https://checkrare.com/new-clinical-trial-testing-on-demand-use-of-deucrictibant-in-patients-with-hereditary-angioedema/

Upcoming Regulatory Decision for LNTH-2501 in the Imaging of Neuroendocrine Tumors by Madaline Spencer| Published on: May 26, 2026

Upcoming Regulatory Decision for LNTH-2501 in the Imaging of Neuroendocrine Tumors by Madaline Spencer| Published on: May 26, 2026 Mauro Cives, MD, Associate Professor of Medical Oncology at the University of Bari, Italy, discusses the upcoming regulatory decision for LNTH-2501 to improve imaging of neuroendocrine tumors (NETs). https://checkrare.com/upcoming-regulatory-decision-for-lnth-2501-in-the-imaging-of-neuroendocrine-tumors/

DUET Clinical Trial of Xywav in Patients With Narcolepsy by Madaline Spencer| Published on: May 29, 2026

DUET Clinical Trial of Xywav in Patients With Narcolepsy by Madaline Spencer| Published on: May 29, 2026 Logan Schneider, MD, Adjunct Clinical Associate Professor of Psychiatry and Behavioral Sciences at Stanford University, discusses the DUET clinical trial of Xywav (low sodium oxybate) in patients with narcolepsy. https://checkrare.com/duet-clinical-trial-of-xywav-in-patients-with-narcolepsy/

Smarter Step: New Tech Helping Amputees By Ivanhoe Broadcast News on June 5, 2026

Smarter Step: New Tech Helping Amputees By Ivanhoe Broadcast News on June 5, 2026 RALEIGH, N.C. (Ivanhoe Newswire) — According to the Amputee Coalition, more than two million people in the United States are living with limb loss. And, that number is expected to double by 2050. Losing a leg doesn’t just change how someone walks — it can change how their entire body moves. For many amputees, years of compensating with other muscles can lead to chronic hips, back, and joint pain. Ivanhoe shows us how technology could change lives https://www.ivanhoe.com/?p=37137&preview=1&_ppp=44d165aa7a

Miles from Maternity Care: AI Helping Expectant Moms By Ivanhoe Broadcast News on June 4, 2026

Miles from Maternity Care: AI Helping Expectant Moms By Ivanhoe Broadcast News on June 4, 2026 RALEIGH, N.C. (Ivanhoe Newswire) — Across the US, more than 35 percent of counties are now considered a maternity care desert — with no birthing hospital, no birth center, and no obstetric clinician. https://www.ivanhoe.com/?p=37134&preview=1&_ppp=dd33a2f874

AI’S Impact on Depression By Ivanhoe Broadcast News on June 3, 2026

AI’S Impact on Depression By Ivanhoe Broadcast News on June 3, 2026 ORLANDO, Fla. (Ivanhoe Newswire) — Artificial Intelligence, or AI for short, has made its way into our everyday lives. Today, more than 65 percent of people use AI on a regular basis. While it can make life easier, some research shows AI may be harmful to your mental health. https://www.ivanhoe.com/?p=37131&preview=1&_ppp=6df9416ddd

Extreme Cells Hold Key to Pregnancy & Cancer By Ivanhoe Broadcast News on June 2, 2026

Extreme Cells Hold Key to Pregnancy & Cancer By Ivanhoe Broadcast News on June 2, 2026 RALEIGH, N.C. (Ivanhoe Newswire) — During pregnancy, a mother and baby are connected by a remarkable organ — the placenta. Researchers now say a single massive cell inside that organ may hold clues to pregnancy complications, certain diseases, and even cancer. These so-called “extreme cells” don’t follow the normal rules of biology, and studying them may help scientists better understand how diseases begin. https://www.ivanhoe.com/?p=37128&preview=1&_ppp=f84fb00356

Arlene’s Fight for 2: Saving Mom & Saving Baby By Ivanhoe Broadcast News on June 1, 2026

Arlene’s Fight for 2: Saving Mom & Saving Baby By Ivanhoe Broadcast News on June 1, 2026 RALEIGH, NC. (Ivanhoe Newswire) — Breast cancer remains the most common cancer among women in the United States with more than 300 thousand new cases expected this year. About 15 % will be triple-negative — a fast-moving form that does not respond to hormone therapies and often requires aggressive treatment. For some women, there’s another layer of complexity — they’re pregnant. Martie salt introduces us to one mom who faced both battles at once. https://www.ivanhoe.com/?p=37125&preview=1&_ppp=4115975174

jueves, 28 de mayo de 2026

Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial Liem T. Nguyena,b,e Send email to liem.nt@vinuni.edu.vn ∙ Kien T. Nguyena,e ∙ Lan T.M. Daoa,e ∙ Van T. Hoanga ∙ Trang T.K. Phana ∙ Nhung T.H. Dinha ∙ et al.

Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial Liem T. Nguyena,b,e Send email to liem.nt@vinuni.edu.vn ∙ Kien T. Nguyena,e ∙ Lan T.M. Daoa,e ∙ Van T. Hoanga ∙ Trang T.K. Phana ∙ Nhung T.H. Dinha ∙ et al. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(26)00150-7/fulltext?dgcid=hubspot_update_feature_updatealerts_ebiom&utm_campaign=update-ebiom&utm_medium=email&_hsenc=p2ANqtz--eN-PeSYMQzVYYXXrkjzFcoIRR6Cnnpqq4cP_TpoEPWSf8RfhuoOX-zmM-fDQKPZE7uQ-UGVcQrinK7qjMklwMRQANyg&_hsmi=420912456&utm_content=420560842&utm_source=hs_email

Transcranial temporal interference stimulation targeting the subthalamic region for motor symptoms in Parkinson's disease: a pilot, randomised, double-blind, sham-controlled crossover study Chenhao Yanga ∙ Yongxin Xua ∙ Yichao Dua ∙ Xiaonan Shena ∙ Tingting Lia ∙ Nan Chenb ∙ et al.

Transcranial temporal interference stimulation targeting the subthalamic region for motor symptoms in Parkinson's disease: a pilot, randomised, double-blind, sham-controlled crossover study Chenhao Yanga ∙ Yongxin Xua ∙ Yichao Dua ∙ Xiaonan Shena ∙ Tingting Lia ∙ Nan Chenb ∙ et al. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(26)00127-1/fulltext?dgcid=hubspot_update_feature_updatealerts_ebiom&utm_campaign=update-ebiom&utm_medium=email&_hsenc=p2ANqtz-90qIaSCtX0-9wJOwZbEDqX_hGQFTuYAsKopdKPQ8fMA6JLUmpCFgpENjQuZWiOShAprfnFOrGbXl-t7PZ8ozZ3lwzyaQ&_hsmi=420912456&utm_content=420560842&utm_source=hs_email

Blood-based biomarker discovery for early pregnancy loss using integrative multi-omics strategies Yue Shia,i ∙ Yongkang Yangb,c,i ∙ Xianghao Guoc ∙ Shuai Shic ∙ Qin Lib,c ∙ Chi Chiu Wanga,d ∙ et al.

Blood-based biomarker discovery for early pregnancy loss using integrative multi-omics strategies Yue Shia,i ∙ Yongkang Yangb,c,i ∙ Xianghao Guoc ∙ Shuai Shic ∙ Qin Lib,c ∙ Chi Chiu Wanga,d ∙ et al. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(26)00135-0/fulltext?dgcid=hubspot_update_feature_updatealerts_ebiom&utm_campaign=update-ebiom&utm_medium=email&_hsenc=p2ANqtz-93LGpatUDNPkdATM4s8RaZjVEFMZ88kEKWDnHfZyvE3h-8QKE1X99QNJEKw_EF7xmblNT4BpsuKVmAHqQuCqnhtojnJA&_hsmi=420912456&utm_content=420560842&utm_source=hs_email

Editorial Towards biology-informed therapies for long COVID eBioMedicine +...

Editorial Towards biology-informed therapies for long COVID eBioMedicine https://www.thelancet.com/journals/ebiom/issue/vol127nonull/PIIS2352-3964(26)X2003-5

Editorial p393 Shared ownership with young people in health research The Lancet Child & Adolescent Health +... +

Editorial p393 Shared ownership with young people in health research The Lancet Child & Adolescent Health https://www.thelancet.com/journals/lanchi/issue/vol10no6/PIIS2352-4642(26)X2004-1 Safety of in vivo gene therapy in children: mechanisms and management of liver injury Rebecca Jeyaraj, MRCPCHa,b,c,e Send email to r.jeyaraj@bham.ac.uk ∙ Li-An K Brown, FRCPathd,e ∙ Barath Jagadisan, MDf ∙ Prof Francesco Muntoni, MDe,g ∙ Julien Baruteau, MD PhDc,e,h ∙ Girish Gupte, MDb ∙ et al. https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(25)00380-3/abstract?utm_campaign=update-lanchi&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanchi&_hsenc=p2ANqtz-9QrxCRagSs_beTr6XJq_XoVjWGW6gSKMSYxR2hLpd1P6j4oUALM441QANXP-ElFBT_hoi88aYoY721gS0UoFamI--fIA&_hsmi=420884426&utm_content=420561182&utm_source=hs_email

Setting priorities for research in addiction Anne Lingford-Hughesa Send email to anne.lingford-hughes@ic.ac.uk ∙ Toto Gronlundb ∙ Eilish Gilvarryc,d on behalf of the James Lind Alliance Priority Setting Partnership for Addiction

Setting priorities for research in addiction Anne Lingford-Hughesa Send email to anne.lingford-hughes@ic.ac.uk ∙ Toto Gronlundb ∙ Eilish Gilvarryc,d on behalf of the James Lind Alliance Priority Setting Partnership for Addiction https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(26)00023-4/abstract?utm_campaign=update-lanpsy&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanpsy&_hsenc=p2ANqtz-8CF8Ml92mDNnLNHY8nuz6FwfLUvUUi24ALE9xMLjq7TaCSjX66o78hTbp8t6-WohKU5h15vvByjU-RJ6hd8bnUyxfYMQ&_hsmi=420895767&utm_content=420561075&utm_source=hs_email

Editorial p445 Maternal depression: improving estimates and care The Lancet Psychiatry +...

Editorial p445 Maternal depression: improving estimates and care The Lancet Psychiatry https://www.thelancet.com/journals/lanpsy/issue/vol13no6/PIIS2215-0366(26)X2004-1

The value of infectious disease conferences The Lancet Infectious Diseases ++... ++

The value of infectious disease conferences The Lancet Infectious Diseases https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00245-8/fulltext?dgcid=raven_jbs_etoc_email Jun 2026 Volume 26Number 6p549-650, e209-e267 https://www.thelancet.com/journals/laninf/issue/vol26no6/PIIS1473-3099(26)X2005-9 Case presentation of patients hospitalised with mpox (subclade Ib/2023sh) including children, adolescents, and adults in South Kivu, Democratic Republic of the Congo: an observational cohort study Luis Flores Girón, MSca,b,c,* ∙ Gustavo Sganzerla Martinez, PhDd,e,h,* ∙ Baganda Ntahuma Daniel, MDb ∙ Alfred Kesheni Bisimwa, MDb ∙ Nkonzi Pacific, MDb ∙ Georges Assumani Martin, BVSca,b,c ∙ et al. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00051-4/fulltext?dgcid=raven_jbs_etoc_feature_laninf Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial Tamiru Shibiru Degaga, MDa,b ∙ Prof Ayodhia Pitaloka Pasaribu, PhDc,d ∙ Rupam Tripura, PhDe,f ∙ Najia Ghanchi, PhDg ∙ Megha Rajasekhar, PhDh ∙ Bipin Adhikari, PhDe,f ∙ et al. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00729-7/fulltext?dgcid=raven_jbs_etoc_feature_laninf

Editorial e349 Climate change and health: closing the gaps The Lancet Public Health + +... +

The 2026 Europe report of the Lancet Countdown on health and climate change: narrowing window for decisive health action Hedi K Kriit, PhDa,b,c Send email to Hedi.kriit@uni-heidelberg.de ∙ José Chen-Xu, PhDd,e ∙ Prof Jan C Semenza, PhDa,c ∙ Hannah Heiliger, PhDf ∙ Prof Anil Markandya, PhDg ∙ Prof Niheer Dasandi, PhDh ∙ et al. https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(26)00025-3/fulltext?dgcid=raven_jbs_etoc_feature_lanpub Editorial e349 Climate change and health: closing the gaps The Lancet Public Health https://www.thelancet.com/journals/lanpub/issue/vol11no6/PIIS2468-2667(26)X2005-9 The effects of the Rx Kids unconditional cash prescription programme during pregnancy and infancy on birth outcomes in the USA: a population-based, quasi-experimental study Sumit Agarwal, MDa Send email to sumitag@med.umich.edu ∙ Prof H Luke Shaefer, PhDb ∙ Yasamean Zamani-Hank, PhDc ∙ Eric Finegood, PhDd ∙ Jenny LaChance, MSe ∙ Prof Mona Hanna, MD https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(26)00055-1/fulltext?dgcid=raven_jbs_etoc_feature_lanpub

Research challenges long standing beliefs about cannabis and male hormones

https://www.news-medical.net/news/20260528/Research-challenges-long-standing-beliefs-about-cannabis-and-male-hormones.aspx The effects of cannabis on the hormonal system and male fertility remain controversial within the scientific community. A study conducted by the University of Geneva (UNIGE), in collaboration with the Swiss Center for Applied Human Toxicology (SCAHT), provides a new answer by showing that cannabis use does not reduce testosterone levels in young men and may even increase its testicular synthesis.

How common spices may improve gut, brain, and metabolic health

https://www.news-medical.net/news/20260528/How-common-spices-may-improve-gut-brain-and-metabolic-health.aspx From cinnamon and turmeric to black pepper and oregano, researchers say common kitchen spices may do far more than add flavor, potentially influencing blood sugar, inflammation, brain function, and even the gut microbiome. Researchers reviewed available literature, particularly studies conducted at the University of California–Los Angeles (UCLA) Center for Human Nutrition, to examine the effects of spices and herbs on human health. This review is available in Nutrition Reviews.

Outcomes of Pegcetacoplan Treatment in Adolescents With C3G and IC-MPGN by Madaline Spencer| Published on: May 22, 2026 +... +...

Outcomes of Pegcetacoplan Treatment in Adolescents With C3G and IC-MPGN by Madaline Spencer| Published on: May 22, 2026 A recent publication in the Clinical Journal of the American Society of Nephrology presented outcomes of pegcetacoplan treatment in adolescents with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). https://checkrare.com/outcomes-of-pegcetacoplan-treatment-in-adolescents-with-c3g-and-ic-mpgn/ Results From the ACUITY Clinical Trial in Patients With Acute Optic Neuritis by Madaline Spencer and James Radke, PhD| Published on: May 22, 2026 Pablo Villoslada, MD, PhD, Founder and Medical Director of Accure Therapeutics and Head of Pathogenesis and New Therapies MS at IDIBAPS in Hospital Clínic in Barcelona, discusses results from the ACUITY clinical trial testing privosegtor to treat patients with acute optic neuritis (AON). The data was recently presented at the American Academy of Neurology Annual Meeting (AAN 2026) in Chicago, IL. https://checkrare.com/results-from-the-acuity-clinical-trial-in-patients-with-acute-optic-neuritis/

Overview of Arginine Vasopressin Deficiency by CheckRare Staff| Published on: May 28, 2026

Overview of Arginine Vasopressin Deficiency by CheckRare Staff| Published on: May 28, 2026 The name of the rare disease central diabetes insipidus was changed in 2024 to better reflect its etiology. CheckRare discussed this disorder with Christopher Romero, MD, a pediatric endocrinologist at Mount Sinai Medical Center, New York City, and Associate Professor of Pediatrics at the Icahn School of Medicine at Mount Sinai. https://checkrare.com/overview-of-arginine-vasopressin-deficiency/

Decision-Making for Managing Myelofibrosis-Related Cytopenias: What Is Best Practice? Authors: Paola Guglielmelli, MD, PhD

https://www.medscape.org/viewarticle/decision-making-managing-myelofibrosis-related-cytopenias-2026a1000ar2?page=1&src=mkmcmr_driv_stan_mscpedu_260528-OUS-HONC-decision-making-managing-myelofibrosis-related-cytopenias-2026a1000ar2-cta&uac=148436CN

Beyond diagnosis and treatment: Delivering holistic care for people living with rare diseases May 2026

https://www.eurordis.org/beyond-diagnosis-and-treatment-delivering-holistic-care-for-people-living-with-rare-disease/ Living with a rare disease impacts every aspect of a person’s life, from education and employment to mental health and social participation. Yet, regardless of whether someone receives a diagnosis or access to treatment, health and social care systems often fail to support them.

How Are Oral SERDs Changing the Management of Advanced HR-Positive Breast Cancer? Authors: Erica L. Mayer, MD, MPH; François-Clément Bidard, MD, PhD

https://www.medscape.org/viewarticle/how-are-oral-serds-changing-management-advanced-hr-positive-2025a1000xkg?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_260527-OUS-HONC-how-are-oral-serds-changing-management-advanced-hr-positive-2025a1000xkg-cta

Coconut Oil Leslie S. Baumann, MD

https://www.medscape.com/viewarticle/coconut-oil-2026a1000gkx?ecd=wnl_edit_tpal_etid8377805&uac=148436CN&impID=8377805 Coconut oil, derived from the dried Cocos nucifera (coconut) fruit, is made up of 90% saturated triglycerides and is used as a skin- and hair-conditioning agent as well as a fragrance ingredient in hundreds of formulations at concentrations ranging from 0.0001% to 70%. Notably, coconut oil also has a long history of traditional medicine use in China and India and in food preparation. Indeed, coconut oil is a staple ingredient in the Sri Lankan diet as well as others in South Asia, Africa, and South America, where coconut is cultivated.

Do We Need to Rethink MS Classification? Andrew N. Wilner, MD; Jodie M. Burton, MD, MSc

https://www.medscape.com/viewarticle/do-we-need-rethink-ms-classification-2026a1000f5p?ecd=wnl_edit_tpal_etid8377805&uac=148436CN&impID=8377805 Andrew N. Wilner, MD: Welcome to Medscape. I'm your host, Dr Andrew Wilner. Today, I have the pleasure of speaking with Dr Jodie Burton. Dr Burton is a neuroimmunologist and clinical associate professor in the departments of Clinical Neurosciences and Community Health Sciences at the University of Calgary, Canada. We're going to discuss a recent publication in JAMA Neurology by Dr Shirani and colleagues about the classification of multiple sclerosis (MS). Welcome, Dr Burton.

DNA origami vaccine nanoparticles improve humoral and cellular immune responses to infectious diseases Yang C. Zeng, Olivia J. Young, Qiancheng Xiong, Longlong Si, Min Wen Ku, Sylvie G. Bernier, Hawa Dembele, Giorgia Isinelli, Tal Gilboa, Zoe Swank, Su Hyun Seok, Anjali Rajwar, Amanda Jiang, Yunhao Zhai, LaTonya D. Williams, Caleb A. Hellman, Chris M. Wintersinger, Amanda R. Graveline, Andyna Vernet, Melinda Sanchez, Sarai Bardales, Georgia D. Tomaras, Ju Hee Ryu, Ick Chan Kwon, …William M. Shih

https://www.nature.com/articles/s41551-026-01614-w?utm_medium=email&_hsenc=p2ANqtz--IfJSyYHc0U7-oUr667PyekarXQaUk6sxxhiyhUjE5ZRS2-6ts9GfkD-655BWV1_ebhztY_1xUnTAyS9NaMkjFcubrDQ&_hsmi=136907737&utm_content=136917285&utm_source=hs_email Current SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccines have shown robust induction of neutralizing antibodies and CD4+ T cell activation; however, CD8+ responses are variable, and the duration of immunity and protection against variants are limited. Here we repurpose our DNA origami vaccine nanotechnology DoriVac to target infectious viruses, namely, SARS-CoV-2, HIV and Ebola. The DNA origami nanoparticle, conjugated with infectious-disease-specific heptad repeat 2 peptides, which act as highly conserved antigens, and CpG adjuvant at precise nanoscale spacing, induces neutralizing antibodies, Th1 CD4+ T cells and CD8+ T cells in naive mice, with significant improvement over a bolus control. Pre-clinical studies using lymph-node-on-a-chip systems validate that DoriVac, when conjugated with antigenic peptides or proteins, induces promising cellular and humoral immune responses in human cells. Moreover, DoriVac bearing full-length SARS-CoV-2 spike protein achieves immune responses comparable to current mRNA vaccine platforms while potentially reducing storage constraints. These results suggest that DoriVac holds potential as a versatile, modular vaccine platform, capable of inducing both humoral and cellular immunities, underscoring its potential future use.

Hypothalamic Menin regulates systemic aging and cognitive decline Lige Leng ,Ziqi Yuan,Xiao Su,Zhenlei Chen,Shangchen Yang,Meiqin Chen,Kai Zhuang,Hui Lin,Hao Sun,Huifang Li,Maoqiang Xue,Jun Xu,Jingqi Yan, [ ... ],Jie Zhang

https://journals.plos.org/plosbiology/article?id=10.1371%2Fjournal.pbio.3002033&utm_medium=email&_hsenc=p2ANqtz-_usNpy06_r8JkxN02BpayZ0-VnIvPr0cujvK_R21pn9qkYDKjYTaIWRFYyNHwxZ0J8vSbyhWy7aM6Sn1tIQYOdUKimlw&_hsmi=136907737&utm_content=136917285&utm_source=hs_email Aging is a systemic process, which is a risk factor for impaired physiological functions, and finally death. The molecular mechanisms driving aging process and the associated cognitive decline are not fully understood. The hypothalamus acts as the arbiter that orchestrates systemic aging through neuroinflammatory signaling. Our recent findings revealed that Menin plays important roles in neuroinflammation and brain development. Here, we found that the hypothalamic Menin signaling diminished in aged mice, which correlates with systemic aging and cognitive deficits. Restoring Menin expression in ventromedial nucleus of hypothalamus (VMH) of aged mice extended lifespan, improved learning and memory, and ameliorated aging biomarkers, while inhibiting Menin in VMH of middle-aged mice induced premature aging and accelerated cognitive decline. We further found that Menin epigenetically regulates neuroinflammatory and metabolic pathways, including D-serine metabolism. Aging-associated Menin reduction led to impaired D-serine release by VMH-hippocampus neural circuit, while D-serine supplement rescued cognitive decline in aged mice. Collectively, VMH Menin serves as a key regulator of systemic aging and aging-related cognitive decline.

Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV +... ++++++

https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/community-acquired Community-Acquired Bacterial Pneumonia Updated the recommendations for preferred and alternative empiric treatment of community-acquired pneumonia (CAP). Added treatment recommendations for patients with CAP for whom a viral etiology is identified. Updated the recommendations on the use of corticosteroids in the management of CAP in hospitalized patients. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/hepatitis-b-virus Hepatitis B Virus Infection Updated the recommendations for people with isolated anti–hepatitis B core antibody to reflect that tenofovir-sparing regimens can also be considered with monitoring of alanine aminotransferase. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/malaria Malaria Noted the potential for false-negative rapid diagnostic tests for Plasmodium falciparum due to emerging histidine-rich protein 2 gene deletions in some regions. Updated the medication options, dosing recommendations, and glucose-6-phosphate dehydrogenase deficiency screening requirements for anti-relapse therapy for P. vivax and P. ovale species infections. Updated the preferred treatment recommendations for pregnant women. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/disseminated Disseminated Mycobacterium avium Complex Disease Clarified the use of molecular assays to identify Mycobacterium avium Complex (MAC) subspecies and mutations associated with macrolide resistance. Updated the guidance on diagnostic criteria and treatment for localized pulmonary MAC disease in keeping with the American Thoracic Society/European Respiratory Society/European Society of Clinical Microbiology and Infectious Diseases/Infectious Disease Society of America joint guideline on the treatment of nontuberculous mycobacterial pulmonary disease. Clarified the criteria for severe MAC disease that might require a third or fourth antimycobacterial drug for treatment. Disseminated Mycobacterium avium Complex Disease Pneumocystis pneumonia https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/pneumocystis Revised the recommendation statement regarding indications for initiating primary prophylaxis for Pneumocystis pneumonia for clarity and simplicity. Syphilis https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/syphilis Recommended serologic screening for syphilis in pregnant women at the first prenatal visit, at 28 weeks’ gestation, and at delivery. Noted that doxycycline post-exposure prophylaxis is an option for syphilis prevention for some individuals. These guidelines are published in an electronic format and updated as changes occur in prevention and treatment science. All updates are developed by the subject matter groups listed in Appendix B and reviewed by scientific content experts. To view or download the guidelines, go to the Adult and Adolescent Opportunistic Infection Guidelines section of the Clinicalinfo website. The guidelines tables and recommendations also can be downloaded as separate PDF files. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/panel-roster?view=full

miércoles, 27 de mayo de 2026

Persistent gaps in skin cancer prevention + + +... +

A multiparameter model (OsteoSC-M3) for early detection and risk stratification of osteoporosis in women: a multicentre cohort study in China Xiaoyan Tenga,d ∙ Ji Qiaob,d ∙ Yang Xuea ∙ Li Weib ∙ Xiaozhong Jic Send email to 1263830302@qq.com ∙ Yuzhen Du https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00150-1/fulltext?dgcid=raven_jbs_etoc_feature_eclinm Oropouche virus: transmission, epidemiology, genetic diversity, and public health implications Lorenzo Subissia Send email to subissil@who.int ∙ James R. Otienoa ∙ Christopher Ruisb,c,d ∙ Ingrid Rabea ∙ Anurag Agrawale ∙ Laith Jamal Abu-Raddadf ∙ et al. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00118-5/fulltext?dgcid=raven_jbs_etoc_feature_eclinm May 2026 Volume 95 https://www.thelancet.com/journals/eclinm/issue/vol95nonull/PIIS2589-5370(26)X2004-1 Persistent gaps in skin cancer prevention eClinicalMedicine https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00255-5/fulltext?dgcid=raven_jbs_etoc_email

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV

https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new Update on Statin Therapy as Primary Prevention of Atherosclerotic Cardiovascular Disease in People With HIV https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/statin-therapy-people-hiv?view=full

Early Palliative Integration for Heart Failure Karel De Pourcq, PhD

https://www.medscape.com/viewarticle/early-palliative-integration-heart-failure-2026a1000hh1

Upcoming Regulatory Decision for LNTH-2501 in the Imaging of Neuroendocrine Tumors by Madaline Spencer| Published on: May 26, 2026

Itvisma Gene Therapy for Patients With Spinal Muscular Atrophy by CheckRare Staff| Published on: May 27, 2026

Itvisma Gene Therapy for Patients With Spinal Muscular Atrophy by CheckRare Staff| Published on: May 27, 2026 John Day, MD, PhD, Director of Neuromuscular Medicine at Stanford University, discusses the development of Itvisma gene therapy for patients with spinal muscular atrophy (SMA). https://checkrare.com/itvisma-gene-therapy-for-patients-with-spinal-muscular-atrophy/

How multi-omics is changing what scientists can see in the human immune system

https://www.news-medical.net/news/20260429/How-multi-omics-is-changing-what-scientists-can-see-in-the-human-immune-system.aspx?utm_source=azonetwork_newsletter&utm_medium=email&utm_campaign=genomics_newsletter_26_may_2026 By combining high-dimensional immune data with advanced computation, researchers are moving closer to predicting vaccine responses, disease risk, and treatment outcomes, but the field still faces major challenges in data quality, validation, and clinical translation.

New colorectal cancer screening guidelines emphasize advanced stool tests

https://www.news-medical.net/news/20260527/New-colorectal-cancer-screening-guidelines-emphasize-advanced-stool-tests.aspx With colorectal cancer a growing concern among younger people, the American Cancer Society has endorsed two new types of stool tests to encourage people to get screened while also recommending a limited role for new blood tests many patients find appealing.

Prenatal forever chemical exposure may affect puberty timing in children

https://www.news-medical.net/news/20260527/Prenatal-forever-chemical-exposure-may-affect-puberty-timing-in-children.aspx An EHU-University of the Basque Country and Biogipuzkoa Health Research Institute study has linked certain chemicals measured during the first trimester of pregnancy to the subsequent onset of puberty in the children. Within the framework of the INMA project, which studies the impact of environmental pollutants on pregnancy and child development, researchers analysed the concentrations of chemicals known as PFAS measured in the mother's blood, and the onset of puberty in girls and boys. The study showed that certain types of PFAS may be slightly associated with the early or late onset of some pubertal characteristics.

Poor lipid metabolism may reduce cognitive performance in teens

Poor lipid metabolism may reduce cognitive performance in teens A new Finnish study shows that blood markers of dysfunctional lipid metabolism are associated with poorer cognitive function in 15-17-year-olds. The findings are significant because brain development during adolescence is rapid, and protecting it from an early age is critical for lifelong brain health. Preventing lipid metabolism dysfunction from childhood may support not only cardiovascular health, but also healthy brain development.

What Does Organic Mean on Food Labels?

https://www.news-medical.net/health/What-Does-Organic-Mean-on-Food-Labels.aspx Organic food labels reflect certified production standards, not guaranteed health superiority. Organic systems can support biodiversity, soil health, and lower residue exposure, but benefits vary by crop, region, and management. The global organic market has grown rapidly over the past two decades due to rising consumer interest in health, environmental sustainability, and food transparency. Despite the growing popularity of organic products, which currently have a market value of over $106 billion USD, the regulations and scientific standards behind organic labeling remain poorly understood by many consumers.

Highlights From San Francisco: The Evolving Role of The Radiation Oncologist in Lower-Grade Glioma Care Authors: Erik P. Sulman, MD, PhD; Mitchel S. Berger, MD; Benjamin M. Ellingson, PhD; Lia M. Halasz, MD; Michael Weller, MD

https://www.medscape.org/viewarticle/1003169?src=mkmcmr_driv_stan_mscpedu_260527-OUS-HONC-1003169-cta&uac=148436CN

Redefining axial spondyloarthritis: more than just back pain The Lancet Rheumatology ++... ++

Redefining axial spondyloarthritis: more than just back pain The Lancet Rheumatology https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(26)00155-4/fulltext?dgcid=raven_jbs_etoc_email Jun 2026 Volume 8Number 6e407-e492 https://www.thelancet.com/journals/lanrhe/issue/vol8no6/PIIS2665-9913(26)X2005-7 Towards global clinical practice guidelines for the management of non-specific low back pain in primary care: a review of current guideline recommendations and how they have changed over the last 30 years Crystian B Oliveira, PhDa,b,c Send email to crystian.oliveira@sydney.edu.au ∙ Prof Bart W Koes, PhDd,e ∙ Rafael Z Pinto, PhDf,g ∙ Adrian C Traeger, PhDa,b ∙ Gustavo C Machado, PhDa,b ∙ Prof Chung-Wei Christine Lin, PhDa,b ∙ et al. https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(26)00077-9/fulltext?dgcid=raven_jbs_etoc_feature_lanrhe Time to pregnancy in women with rheumatoid arthritis who want to conceive treated according to a treat-to-target approach: a comparison of an observational cohort with a historical reference cohort Cornelia H Quaak, MDa,b Send email to c.witte-quaak@erasmusmc.nl ∙ Esther Röder, PhDa ∙ Hetty M Wintjesa ∙ Anneke J van Steensel-Boona ∙ Annemarie G M G J Mulders, MD PhDc ∙ Laura J C Kranenburg-van Koppen, MD PhDa ∙ et al. https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(26)00001-9/abstract?dgcid=raven_jbs_etoc_feature_lanrhe

Editorial p437 Diabetes-related complications: an evolving spectrum The Lancet Diabetes & Endocrinology +... +++

Editorial p437 Diabetes-related complications: an evolving spectrum The Lancet Diabetes & Endocrinology https://www.thelancet.com/journals/landia/issue/vol14no6/PIIS2213-8587(26)X2004-6 Continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes: a randomised, multicentre, open-label, superiority trial Emma G Wilmot, PhDa,b Send email to emma.wilmot@nottingham.ac.uk ∙ Patrick Moore, MRCGPc ∙ Prof Thozhukat Sathyapalan, PhDd,e ∙ Prof Pratik Choudhary, MDf,g ∙ Jonathan Z M Lim, PhDh ∙ Prof Sankalpa Neupane, PhDi,j ∙ et al. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(26)00076-8/fulltext?dgcid=hubspot_update_feature_updatealerts_landia&utm_campaign=update-landia&utm_medium=email&_hsenc=p2ANqtz-_xluE4-r7gy5mW3cv0mHuxzmTwmvAhnv2EgCbjtIDdhP_Iv4z9R85BAtzEkQwGpAFKHTe349DiOYFUltwzIlMd8rR7ig&_hsmi=420591049&utm_content=420425813&utm_source=hs_email Safety, tolerability, pharmacokinetics, and efficacy of burosumab in infants with X-linked hypophosphataemia: an open-label, multicentre, non-randomised study Prof Agnès Linglart, MD PhDa ∙ Francesco Emma, MDb ∙ Prof Justine Bacchetta, MD PhDc,d ∙ Francisco de la Cerda, MD PhDe ∙ Prof Wesley Hayes, MB BChirf ∙ Moira Cheung, MBBS PhDg ∙ et al. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(26)00013-6/abstract?utm_campaign=update-landia&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_landia&_hsenc=p2ANqtz-8UY7J_onTjWe-OATN2C9a-Vc5hjr8GENsDoyBXKfVwGILmmWiwdbawjUBOPG8uKJIsEuSFAn0Wxggr-uv-19Fh998VLQ&_hsmi=420591049&utm_content=420425813&utm_source=hs_email Natural history of thyroid function in ageing: an individual participant data analysis of 137 488 participants from 31 prospective cohort studies Yanning Xu, MDa,b,c ∙ Ola Hysaj, Mscd,e ∙ Xiaoyi Qi, MDa,b ∙ Martin Feller, MDd ∙ Alessandro Pingitore, MDf ∙ Suzanne J Brown, BScg ∙ et al. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(26)00009-4/abstract?utm_campaign=update-landia&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_landia&_hsenc=p2ANqtz-8KZNT-6onbs6ezSnVZPwUEKLaPpbUSnKuC6et0GvzAf5FXyjqCvewXTPZHkatf-Ege4a43cO3BtU36W75A0FIeHvO3RA&_hsmi=420591049&utm_content=420425813&utm_source=hs_email

Editorial p533 The US Parkinson's disease community demands prevention The Lancet Neurology +... +++

Editorial p533 The US Parkinson's disease community demands prevention The Lancet Neurology https://www.thelancet.com/journals/laneur/issue/vol25no6/PIIS1474-4422(26)X2004-X Safety, tolerability, and efficacy of acetazolamide in idiopathic normal pressure hydrocephalus (DRAIN) in Sweden: a randomised, double-blind, placebo-controlled, phase 2 trial Johan Virhammar, PhDa Send email to johan.virhammar@uu.se ∙ Oskar Fasth, MDa ∙ Maria Ekblom, Msca ∙ Oskar Ekman, MDa ∙ Nils Holmstrandb ∙ David Fällmar, PhDb ∙ et al. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00126-2/abstract?utm_campaign=update-laneur&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_laneur&_hsenc=p2ANqtz-_Mn2o_yBRyEKuL70_TRj7JiTD2mVaSC7v6VU21YwBnXKCW_X_trqivkayL_VTUNgWWpJ6_7-uWO4SRnG6oi8K8DFoEtA&_hsmi=420598221&utm_content=420423128&utm_source=hs_email Safety and efficacy of the anti-α-synuclein monoclonal antibody amlenetug for the treatment of patients with multiple system atrophy (AMULET): a phase 2, randomised, double-blind, multicentre trial Lotte Kjærsgaard, MDa ∙ Jonas Wiedemann, MSca ∙ Prof Wolfgang Singer, MDb ∙ Atsushi Takeda, MDc ∙ Anna-Karin Berger, PhDa ∙ Mimi Folden Flensburg, DVM PhDa ∙ et al. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00100-6/abstract?utm_campaign=update-laneur&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_laneur&_hsenc=p2ANqtz-9KF3XIEfkWNGopKUFNNumxv3pXcoe2EPIMPZ52qa5d3QyrhNF5qYJZpkGsZdVk70Kp0pJh7_xpmGv-fF-OcJWH1yWmsA&_hsmi=420598221&utm_content=420423128&utm_source=hs_email New evidence on the clinical, genetic, and biochemical bases of GBA1-Parkinson's disease: prospects for treatment Elisa Menozzi, MD PhDa,b ∙ Marco Toffoli, MD PhDa,b ∙ Prof Michela Deleidi, MD PhDb,c ∙ Prof Donato A Di Monte, MDb,d ∙ Prof Fabio Blandini, MD PhDb,e,f ∙ Prof Dimitri Krainc, MD PhDg ∙ et al. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00090-6/abstract?utm_campaign=update-laneur&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_laneur&_hsenc=p2ANqtz-9C-m4aOGYD5aKPQ9zi6QCjyqSEXSbbIGyTSDFFFpWhQEccFB5Ho4pPcRHelIHz012fBfzF1_RepTkEY_dMKV_B_XuhCg&_hsmi=420598221&utm_content=420423128&utm_source=hs_email

Combination therapy doubles one-year survival in pancreatic cancer trial Findings from the randomized trial suggest that modulating the tumour microenvironment alongside chemotherapy may offer a new strategy for improving outcomes in pancreatic cancer Written byBree Foster, PhD

https://www.drugdiscoverynews.com/combination-therapy-doubles-one-year-survival-in-pancreatic-cancer-trial-17121?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9RjxJ5AZAB6xc-u4klI7ipE7m3TNkJzTFeqS9BgF8sKXBfnuZM3YdZDzZ6GCtBHTzDoDxq03B5R8KLzXFyk1NPbXpDhQ&_hsmi=420563864&utm_content=420563864&utm_source=hs_email A drug developed at Northwestern University has shown a promising survival advantage in patients with metastatic pancreatic cancer, a disease that remains among the deadliest solid tumours and is projected to become the second leading cause of cancer-related deaths in the US within the next decade.

How an enzyme helps lung cancer survive radiation, and how to stop it Researchers identified a mitochondrial enzyme that shields lung cancer cells from a radiation-induced cell death process — and then found that an existing arthritis drug can disable that shield. Written byAndrea Corona

https://www.drugdiscoverynews.com/how-an-enzyme-helps-lung-cancer-survive-radiation-and-how-to-stop-it-17144?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-91vqyJZuy4gJIWMn0Hb45mQSZ5-nnAUxF-j1kIISeo5MLmxGgGYh6cQL2c8yT6OcMBf_h9DQkWTRfB7rYgM1FzHoht3A&_hsmi=420563864&utm_content=420563864&utm_source=hs_email Radiation therapy is among the most widely used treatments for lung cancer, but its effectiveness is frequently undermined by a familiar problem: Tumors that initially respond to treatment develop resistance and begin growing again. How exactly that resistance forms has remained incompletely understood, and the mechanisms that allow cancer cells to survive radiation-induced damage continue to be an active area of investigation.

Designing microbiome therapies at scale starts with manufacturing As the field moves from fecal transplants toward defined bacterial consortia, the technical gaps in design, analytics, and co-cultivation are coming into sharper focus. Written byAndrea Corona

https://www.drugdiscoverynews.com/designing-microbiome-therapies-at-scale-starts-with-manufacturing-17183 Microbiome-based therapeutics have accumulated a compelling body of clinical evidence over the past decade. What they have lacked is the manufacturing and design infrastructure to turn that rationale into reproducible, scalable drugs. Munich-based mbiomics is attempting to build that infrastructure.

Novel genetic target for fragile X syndrome could improve brain function Using an unbiased molecular screen, researchers found a new gene that could be targeted to treat fragile X syndrome. Written byAllison Whitten, PhD

https://www.drugdiscoverynews.com/novel-genetic-target-for-fragile-x-syndrome-could-improve-brain-function-17189 Fragile X syndrome (FXS) — the most commonly inherited cause of both intellectual disability and autism spectrum disorder — results from a mutation in the FMR1 gene (Fragile X messenger ribonucleoprotein 1). Though it’s just a single gene and should theoretically be a great candidate for gene therapy, preclinical and translational work targeting the FMR1 gene has so far not led to a successful treatment of the disorder.